Accelerated partial breast irradiation for early-stage breast cancer: Controversies and current indications for use

Current Treatment Options in Oncology

Volumn 14, Issue 1, 2013, Pages 51-65

  Klepczyk, Lisa C ^a   Keene, Kimberly S ^a   De Los Santos, Jennifer F ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Accelerated; APBI; Breast cancer; Breast conservation; Lumpectomy; Partial breast; Radiation

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TRASTUZUMAB;

ACCELERATED PARTIAL BREAST IRRADIATION; ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; DIET THERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRACAVITARY BRACHYTHERAPY; LIFESTYLE MODIFICATION; MASTECTOMY; MEDICAL SOCIETY; MULTICATHETER INTERSTITIAL BRACHYTHERAPY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SAFETY; PERSONALIZED MEDICINE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RADIATION INJURY; RADIATION SAFETY; RECURRENCE RISK; RECURRENT SELECTION; RETROSPECTIVE STUDY; SKIN SPARING MASTECTOMY; SURGICAL TECHNIQUE; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; TREATMENT INDICATION; WHOLE BREAST RADIATION THERAPY;

EID: 84873722773     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0213-5     Document Type: Article

References (89)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Conservation Cooperative Group. J Natl Cancer Inst Monogr. 1992;11:19-25.
3. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-50.
4. Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(4):697-702.
5. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-41.
6. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-32.
7. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996;14(5):1558-64.
8. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001. Consensus guidelines from experts in radiation oncology on appropriate use of APBI outside of a clinical trial.
9. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59-68.
10. Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol 2012;19(10):3275-81.
11. Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996;14(11):3009-17.
12. Nano MT, Gill PG, Kollias J, et al. Psychological impact and cosmetic outcome of surgical breast cancer strategies. ANZ J Surg. 2005;75(11):940-7.
13. Simmons RM, Fish SK, Gayle L, et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol. 1999;6(7):676-81.
14. Pelad AW, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012;19(11):3402-9.
15. Bellon JR, Harris EE, Arthur DW, et al. ACR Appropriateness Criteria© conservative surgery and radiation - stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast J. 2011;17(5):448-55.
16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practical Guidelines in Oncology: Breast Cancer Version 3.2012. 2012;Available at www.nccn.com.
17. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
18. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-34.
19. van de Vijver MJ, He YD, Van'T Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
20. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
21. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120(3):655-61.
22. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72.
23. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.
24. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20.
25. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998;351(9114):1451-67.
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
28. Dowsett M, Cuzick J, Ingel J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-18.
29. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-16.
30. Nattinger AB, Hoffmann RG, Kneusel RT, et al. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet. 2000;356(9236):1148-53.
31. Gilligan MA, Kneusel RT, Hoffmann RG, et al. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care. 2002;40(3):181-9.
32. Offerson BV, Overgaard M, Kroman N, et al. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol. 2009;90(1):1-13.
33. Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103(4):362-8.
34. Edmundson GK, Vinici FA, Chen PY, et al. Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys. 2002;52(4):1132-9.
35. Wilder RB, Curcio LD, Khanijou RK, et al. A Contura catheter offers dosimetric advantages over a MammoSite catheter that increase the applicability of accelerated partial breast irradiation. Brachytherapy. 2009;8(4):373-8.
36. Hattangadi JA, Powell SN, MacDonald SM, et al. Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83(3):791-800.
37. Khan AJ, Arthur D, Vicini F, et al. Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial. Ann Surg Oncol. 2012;19(5):1477-83.
38. Patel RR, Becker SJ, Das RK, et al. A dosimetric comparison of accelerated partial breast irradiation techniques: multicatheter interstitial brachytherapy, three-dimensional conformal radiotherapy, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;68(3):935-42.
39. Weed DW, Edmundson GK, Vicini FA, et al. Accelerated partial breast irradiation: a dosimetric comparison of three different techniques. Brachytherapy. 2005;4(2):121-9.
40. Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1124-30.
41. Sher DJ, Wittenberg E, Suh WW, et al. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74(2):440-6.
42. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91-102. One of only four randomized, controlled trials published to date on APBI.
43. Veronesi U, Orecchia R, Luini A, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat. 2010;124(1):141-51.
44. Orecchia R, Ciocca M, Lazzari R, et al. Intraoperative radiation therapy with electrons (ELIOT) in early-stage breast cancer. Breast. 2003;12(6):483-90.
45. Shah C, Arthur D, Riutta J, et al. Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment aids, treatment paradigms, and risk reduction. Breast J. 2012;18(4):357-61.
46. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599-609.
47. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34(5):508-13.
48. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657-63.
49. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111-8.
50. Land SR, Kopec JA, Julien TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28(25):3929-36.
51. Coen JJ, Taghian AG, Kachnic LA, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1209-15.
52. Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1095-100.
53. Paskett ED, Dean JA, Oliveri JM, et al. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012;30(30):3726-33.
54. Shah C, Vicini FA. Breast-cancer related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys. 2011;81(4):907-14.
55. Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105 Suppl 1:S52-73.
56. Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815-40.
57. Chlebowski RT, Blackburn GL, Hoy MK, et al. Survival analysis from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome [abstract]. J Clin Oncol 2008;26(15S,Part I) Abstr 522.
58. Livi L, Buonamici FB, Simontacchi G, et al. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys. 2010;77(2):509-15.
59. Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(1):71-8. Article raises concern with regards to the use of IMRT for APBI.
60. Pignol JP, Rakovitch E, Keller BM, et al. Tolerance and acceptance results of a Palladium-103 permanent breast seed implant phase I/II study. Int J Radiat Oncol Biol Phys. 2009;73:1482-8.
61. Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65(5):1572-8.
62. Bush DA, Slater JD, Garberoglio C, et al. A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. Cancer J. 2007;13(2):114-8.
63. Wang X, Amos RA, Zhang X, et al. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys. 2011;80(5):1464-72.
64. Kozak KR, Smith BL, Adams J, et al. Accelerated partial breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66(3):691-8.
65. Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19(4):833-42.
66. Fisher ER, Anderson S, Redmond C, et al. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8(3):161-6.
67. Gage I, Recht A, Gelman R, et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33(2):245-51.
68. Liljegren BG, Bergh HJ, Lindgren A, et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17(8):2326-33.
69. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7):997-1003.
70. Malmstrom P, Holmberg L, Anderson H, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003;39(12):1690-7.
71. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology. Cancer. 2002;95(10):2059-67.
72. Bartelink H, Horiot J, Poortmans PM, et al. Impact of higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259-65.
73. Antonucci JV, Wallace M, Goldstein NS, et al. Difference in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow up. Int J Radiat Oncol Biol Phys. 2009;74(2):447-52. Publication reports equal rates of ipsilateral breast tumor recurrence in patients receiving APBI compared with those receiving WBRT.
74. Beitsch PD, Wilkinson JB, Vicini FA, et al. Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite® Registry Trial. Ann Surg Oncol 2012;19(10):3165-70.
75. Arthur DW, Winter K, Kuske RR, et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of 95-17. Int J Radiat Oncol Biol Phys. 2008;72(2):467-73.
76. Vicini F, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77(4):1120-7. Phase II trial shows early efficacy for the newest method of APBI delivery.
77. Smith GL, Xu Y, Smith BD. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012;307(17):1827-37. Recent controversial study describes increased mastectomy rates in patients treated with APBI by multicatheter interstitial brachytherapy.
78. Cuttino LW, White JR, Rabinovitch R, et al. Accelerated partial-breast irradiation: trial by media or by science? Int J Radiat Oncol Biol Phys. 2012;83(4):1075-7.
79. Khan AJ, Vicini FA, Beitsch P, et al. Local control, toxicity, and cosmesis in women >70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. Int J Radiat Oncol Biol Phys. 2012;84(2):323-30.
80. Kaufman SA, DiPetrillo TA, Price LL, et al. Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast cancer. Brachytherapy. 2007;6(4):286-92.
81. Whelan T, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011;29(Abstr LBA1003 Suppl):S779.
82. Chen PY, Vicini FA, Benitez P, et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer. 2006;106(5):991-9.
83. Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112(4):758-66.
84. Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(4):991-7.
85. Berrang TS, Olivotto I, Kim DH, et al. Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81(5):1220-7. Phase II, multi-center study shows excellent tumor control with minimal toxicity at 3 years.
86. Julian TB, Costantino JP, Vicini FA, et al. A randomized phase III study of conventional whole breast irradiation (WBI) vs partial breast irradiation (PBI) for women with stage 0, 1, or 2 breast cancer: NSABP B-39/RTOG 0413. 2011;San Antonio Breast Cancer Symposium:Abstract OT2-06-02.
87. Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol). 1993;5(5):278-83.
88. Dowdell DJ, Dyker K, Brown J. A randomised study of whole-breast vs. tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol). 2005;17(8):618-22.
89. Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma: 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69(3):694-702.